Global Footprint Adragos operates six production sites across France, Germany, Norway, Switzerland and Japan, plus a development site in Greece, enabling regional manufacturing and supply security. This multi region footprint supports nearshoring, diversified supply chains and faster time-to-market for global clients.

Sterile Capacity Growth Strategic acquisitions and investments have expanded sterile fill and finish capabilities, including a large European sterile injectables plant and the Halden, Norway site, complemented by a new liquid filling line in Leipzig. This positions Adragos to meet rising demand for sterile injectable products.

Full service CDMO Capabilities cover end-to-end development and manufacturing for small molecules and biologics, including sterile and non sterile liquids, solids and semi solids, with fill and finish in vials and pre filled syringes. The Greece development site supports rapid tech transfer and scale up.

Strategic Partnerships Recent collaboration with Towa Pharmaceutical to secure stable supply of off patent medicines and the UK launch of Isoprenaline demonstrate a track record of market-ready partnerships and product introductions that can be extended to co development, exclusive supply or pipeline deals.

Leadership Momentum New CEO Konstantinos Rengis appointed in May 2026 signaling strategic realignment and growth initiatives aligned with expanding capacity, integrating acquired sites and expanding international sales efforts. This timing offers opportunities to engage on long term partnerships and capacity planning.